

48th EUROPEAN CYSTIC FIBROSIS CONFERENCE

4 – 7 JUNE 2025 | MILAN, ITALY

The challenges of managing the neuropsychiatric and psychological effects of modulators: Practical and clinical implications

Tuesday, June 3
14:00 – 18:00

Room: Meeting N4+N5

This course is organized by the European Psychosocial Special Interest Group (EPSIG) and the ECFS Mental Health Working Group. We will explore how CF teams are managing the neuropsychiatric and psychological effects of modulators. This course will include a review of the evidence on side-effects related to new genetic modulators as well as strategies CF Teams are using to manage them. The course will include case presentations on the assessment of side-effects and clinical interventions that have been used to address them. We will emphasize practical approaches to screening and intervention in this new era of modulator therapy. Cases will cover the life span from childhood through adulthood.

Speaker: Beth A. Smith
Moderators: Sonia Graziano & Riccardo Ciprandi

14:00 – 14:10 Welcome and Introduction

Sonia Graziano, IT & Riccardo Ciprandi, IT

14:10 – 16:10 CFTR modulators & neuropsychiatric symptoms:

What has been observed? What do we make of it?

How do we manage it? Next steps: New research

Beth A. Smith

16:10 – 16:30 Coffee break

16:30 – 18:00 Clinical Cases – Panel discussion

Alexandra L Quittner, US & Riccardo Ciprandi, IT & Sonia Graziano, IT
& Jacqueline Boekhoff, NL & Anna Georgiopoulos, US.



Dr. Smith is a Professor of Psychiatry and Pediatrics at the Jacobs School of Medicine and Biomedical Science, University at Buffalo, where she serves as Chair of the Department of Psychiatry and chief of the Division of Child and Adolescent Psychiatry. She also serves as president of UBMD Psychiatry and chief of Behavioral Health for Kaleida Health. Dr. Smith is the founding chair of the Cystic Fibrosis Foundation's Mental Health Advisory Committee whose mission is to promote and support the mental well-being of individuals with CF and their families by partnering with CF Care Centers to provide screening, preventative interventions, and ongoing innovative services. In addition to her extensive clinical work with patients with CF, Dr. Smith has been a leader in studying psychiatric comorbidities and therapies for patients with CF. She was recently awarded a \$3 million grant from the CF Foundation to lead TIDES 2.0, a national epidemiological study to assess mental health in children with CF under 12 years.